Chlorthalidone - A renaissance in use?

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2037-2039

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL PLUS CHLORTALIDONE; CATAPRES DIU; CHLORTALIDONE; CHLORTALIDONE PLUS RESERPINE; CHLORTHALIDONE PLUS CLONIDINE; CHLORTHALIDONE PLUS LOSARTAN; ELECTROLYTE; HYDROCHLOROTHIAZIDE; LIPID; TENOCLOR; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; ELECTROLYTE DISTURBANCE; ERYTHROCYTE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CHLORTHALIDONE; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; LOSARTAN;

EID: 68949146807     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903158956     Document Type: Review

References (16)

1. Meldrum NU, Roughton FJ. Carbonic anhydrase: its preparation and properties. J Physiol (London) 1933;80:113-132
2. Schwartz WB. The effect of sulfanilamide on salt and water excretion in congestive heart failure. N Engl J Med 1949;240:173-177
3. Stender EG, Wirz H, Pulver R. Hygroton (G 33,182), a new saluretic and diuretic with protracted action. Schweiz Med Wochenschr 1959;89:1126-1130
4. Finnerty FA, Kakaviatos N, Chupkovich V. Value of chlorthalidone plus reserpine in moderately severe and severe hypertensions. Circulation 1965;32:13-18
5. Pareek A, Basavanagowdappa H, Zawar SD, et al. A randomized, comparative study evaluating the efficacy and tolerability of losartan low-dose chlorthalidone (6.25-mg) combination with losartan-hydrochlorothiazide (12.5-mg) combination in Indian patients with mild-to-moderate hypertension. Expert Opin Pharmacother 2009;10:1529-1536
6. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-2571
7. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-1628
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264
9. Allhat Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997
10. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544 (Pubitemid 37430155)
11. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
12. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358 (Pubitemid 43740274)
13. Materson BJ, Oster JR, Michael UF, et al. Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin Pharmacol Ther 1978;24:192-814.
14. Riess W, Dubach UC, Burckhardt D, et al. Pharmacokinetic studies with chlorthalidone (Hygroton) in man. Eur J Clin Pharmacol 1977;12:375-8215. (Pubitemid 8246723)
15. Chen TM, Chiou WL. Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol 1992;30:34-716.
16. Izzo JL, Sica DA. Antihypertensive drugs: pharmacologic principles and dosing effects. In: Izzo J, Sica DA, Black H, editors, Hypertension primer, 4th edition. Dallas, TX: American heart association, 2008. p. 432-435